 "Drugmaker Merck has strong fourth quarter as Covid-19 treatment debuts")
The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker's COVID-19 treatment debuted with nearly $1 billion in sales.
Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday.
Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion.
Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street's per-share projections of $1.53, according to a survey by the data firm FactSet.
Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts.
The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue.
Also Read
Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue.
Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in early trading.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)